Going from stealth to a $150 million series B in five months may seem fast, but, for Rapport Therapeutics, 10 years of toiling in the labs at Johnson & Johnson beforehand helped the neurological ...
Rapport Therapeutics, a company whose neuroscience technology comes from Johnson & Johnson, joined the public markets Friday, raising $154 million for proof-of-concept testing of a lead program in ...
A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 157% in premarket trading. The study enrolled 30 ...
Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
NEW YORK--(BUSINESS WIRE)--Rapport, the global out-of-home (OOH) media buying and planning agency arm of IPG Mediabrands, today announced the launch of their newest offering for U.S. clients: ...
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and ...
Conventional wisdom and long-standing apparent research like NLP (neuro-linguistic programming) and Dale Carnegie’s book How to Win Friends and Influence People, would have us believe that building ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback